Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease

Cardiol Rev. May-Jun 2008;16(3):142-53. doi: 10.1097/CRD.0b013e31815c8048.

Abstract

Urotensin II was first identified over 30 years ago as a potent vasoconstrictor, and the identification of its receptor in the heart, lungs, blood vessels, and brain have made it a potential target for human pharmacotherapy. Current research would suggest that urotensin II plays a major role in the pathophysiology of various cardiovascular disease entities. This article discusses the biologic effects of urotensin under normal and pathophysiologic conditions, and reviews the research experiences with synthetic urotensin blockers in the treatment of various cardiovascular illnesses.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / metabolism*
  • Humans
  • Myocardial Contraction
  • Quinolines / pharmacology
  • Receptors, G-Protein-Coupled / antagonists & inhibitors*
  • Receptors, G-Protein-Coupled / metabolism
  • Sulfonamides / pharmacology
  • Urea / analogs & derivatives
  • Urea / pharmacology
  • Urotensins / antagonists & inhibitors*
  • Urotensins / chemistry
  • Urotensins / metabolism*
  • Vasoconstrictor Agents

Substances

  • Biomarkers
  • Quinolines
  • Receptors, G-Protein-Coupled
  • SB-611812
  • Sulfonamides
  • UTS2R protein, human
  • Urotensins
  • Vasoconstrictor Agents
  • Urea
  • urotensin II
  • 1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea